Glenmark Pharmaceuticals Limited has announced the launch of Methylene Blue Injection USP 50 mg/10 mL (5 mg/mL) single-dose vials in the United States through its US subsidiary Glenmark Pharmaceuticals Inc. USA, based in Elmwood Park, New Jersey. The announcement was made on June 17, 2026.
Glenmark's Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug ProvayBlue Injection of Provepharm SAS, approved under NDA 204630. The product is approved only for the indications listed in Glenmark's approved label from the US Food and Drug Administration.
IQVIA sales data for the 12-month period ending April 2026 reported the ProvayBlue Injection market achieved annual sales of approximately USD 19 million. This figure includes brand sales and all available therapeutic equivalents. IQVIA National Sales Perspectives data covering retail and non-retail channels provided the market estimate.
Marc Kikuchi, President and Business Head, North America at Glenmark, said the launch expands access to affordable medicines for healthcare institutions and patients in the United States. The product broadens Glenmark's institutional portfolio in the US market.
Glenmark Pharmaceuticals Limited is listed on NSE under scrip code GLENMARK and on BSE under scrip code 532296. Glenmark operates in over 80 countries with 11 manufacturing facilities across four continents. Glenmark maintains six research and development centres supporting its global operations. Glenmark was ranked among the top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.
Glenmark's portfolio spans branded, innovative, generics, and consumer health products with a focus on respiratory, dermatology, and oncology. Glenmark's global commercial presence extends across more than 80 countries.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.